Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

BACKGROUND: Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis. OBJECTIVE: To assess safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Camm, A John, Derfuss, Tobias, Sprenger, Till, Davies, Martin, Piotrowska, Alexandra, Ni, Pingping, Harada, Tomohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196590/
https://www.ncbi.nlm.nih.gov/pubmed/28911260
http://dx.doi.org/10.1177/1352458517728343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196590/
https://www.ncbi.nlm.nih.gov/pubmed/28911260
http://dx.doi.org/10.1177/1352458517728343

Ejemplares similares